Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

@article{Reid2005ComparisonOA,
  title={Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.},
  author={Ian R Reid and Paul D E Miller and Kenneth W. Lyles and W. D. Fraser and Jacques P Brown and Youssef Saidi and Peter G Mesenbrink and Guoqin Su and Judy Pak and Ken Zelenakas and Monica E Luchi and Peter Richardson and David Hosking},
  journal={The New England journal of medicine},
  year={2005},
  volume={353 9},
  pages={898-908}
}
BACKGROUND The advent of bisphosphonates advanced therapy for Paget's disease, but more effective and convenient agents are needed to increase adherence. Zoledronic acid, a bisphosphonate administered as a single intravenous infusion, might meet these needs. METHODS In two identical, randomized, double-blind, actively controlled trials of 6 months' duration, we compared one 15-minute infusion of 5 mg of zoledronic acid with 60 days of oral risedronate (30 mg per day). The primary efficacy end… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 108 extracted citations

Efficacy of zoledronic acid treatment in Paget disease of bone

Osteoporosis International • 2014
View 3 Excerpts
Highly Influenced

Use of zoledronic acid in the treatment of Paget’s disease

Therapeutics and clinical risk management • 2007
View 2 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Anlimotptive effi ? ct of a single infusion of microgram quan . titie 1 ; of zoledtonate in Paget ' s dise . ase of bone

Arden-CordoneM, ES Sirls, KW Lyles
Bone • 2004

: lcflardt P , et al . llltravenous zoledronic acid in postmenopausal women with low bone mineral density

JP ReidIR.Brown, Bun
N l ! nglJ Med • 2002

Mineral binding affiniti ~ and zeta potentials of bis • phospbon . atet

TangR. GuldeS Nancoll. asGH, IU Bbeti·ooFJ.Phipps, Russell RGG
J Bone Mine : Re . I • 2002

Roge : i : 11 MJ , Ph ; mnacologic profile of : ZOledronic acid : a hi 8 hly potmt inhibitor of bone M 101 . pti 0 n

Green
Drug Dev • 2002

Strucnue - activity relationships fur inhibition offunesyl diphospbate 6 } ' 11 th . ase in vitro and inhibition of hone resoiption in vivo by nittogencontainiog biaphosphonatcs

JB Dunford, I Thompson, FP Coxon
J Pbarm . acol & p Thez • 2001

Prevalence of pdric Paget ' s disease of bone in the United States

M. D. cajeMoniz, M. D. John Walsh, S. R. N. Pat San, DA HffllENCUl.AltmanRD.Bloch, WA Murphy
J Bone Mlner Res • 2000

A randomized , double - blind comparison of risedronate and etidronace in the tteatment of Paget ' s disease of bone

PD Miller, JP Brown, MS Hoseyni, DW Axelcod
Am J Med • 1999

New illsightlS in 10 the molecular mechanisms of action of bi . sphos • phonatrs

MJ Rogers
Bone • 1999

The epidemiology of Paget ' s disease in Brlt : ain : is the prev . alence decre . 11 ing ?

C Cooper, IC Schafht'll.de, B Dennis011, S Kdlingniy, D. GuyuP.Batke.r
J Booe Miner • 1999

The phannacology ofbisphospbonam 1 and new insights into their mechanisms of ac • tion

RG Russell, MJ Rogers, JC Frith
J Bone Miller Rl ? S • 1999

Similar Papers

Loading similar papers…